Abstract

Genome engineering can greatly enhance successful drug discovery. CRISPR is quickly proving to be the tool for the job, with its precision editing capabilities and minimal off-target effects. Leveraging the power of CRISPR can accelerate progress across the drug discovery pipeline and ultimately lead to more and better-validated
drugs entering the clinic. Knowing the genetic landscape of a drug target increases its chances of success by two-fold! Leveraging automated platforms, Synthego provides high throughput CRISPR solutions for basic research, target identification and validation, disease modeling, and preclinical studies. As an example, we’ll show here how Synthego supported the NIH in the iPSC Neurodegeneration Initiative (iNDI) project.